Vigil Neuro
Borislav Dejanovic currently serves as Senior Director of Translational Sciences and External Innovation at Vigil Neuroscience, leading efforts in target identification, preclinical studies, and biomarker discovery for neurodegenerative disease therapeutics since April 2022. Previously, Borislav held various roles at the Broad Institute of MIT and Harvard, including Director of Translational Sciences and External Innovation, where the focus was on molecular pathomechanisms of neurodegenerative and psychiatric diseases. Prior experience includes senior positions at Genentech, focusing on Alzheimer's disease, and a scientific leadership role at the University of Cologne. Educational credentials include a Ph.D. in Biochemistry and Molecular Biology and a Bachelor of Science in Biochemistry from the University of Cologne, complemented by a research semester at Yale School of Medicine.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.